Physician profile
Renuka Bhatt
NPI 1316128861
$3,138.96
in general payments reported to CMS, 2019-2025
19 companies · $779 in 2025
The $779 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2021: $403 · 2022: $240 · 2023: $610 · 2024: $569 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,882 · Education: $76.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.32 |
| Education | $76.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.71 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $451.80 | 2021-2025 | Blu-U, Ilumya, Odomzo |
| Lilly USA, LLC | $292.18 | 2023 | Taltz, Olumiant |
| Inspire Medical Systems, INC. | $250.46 | 2024-2025 | Inspire |
| Pfizer INC. | $218.54 | 2019-2023 | |
| Genzyme Corporation | $198.38 | 2023-2025 | |
| Galderma Laboratories, L.P. | $168.26 | 2024-2025 | Nemluvio |
| Genentech USA, INC. | $131.05 | 2021 | |
| Intercept Pharmaceuticals, INC. | $120.65 | 2021 | |
| Novartis Pharmaceuticals Corporation | $114.22 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $85.85 | 2019 | |
| Ucb, INC. | $61.91 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $36.52 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $31.67 | 2024 | Libtayo |
| Amgen INC. | $28.44 | 2025 | Otezla |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $24.26 | 2025 | Simponi Aria, Simponi, Tremfya |
| Organon LLC | $23.31 | 2025 | Vtama |
| Regeneron Pharmaceuticals, INC. | $21.99 | 2025 | Libtayo |
| Journey Medical Corporation | $14.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renuka Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.